{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:43:23Z","timestamp":1794300203322,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023446","name":"Scleroderma Association of British Columbia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023446","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Exploration of cytokine levels in systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF) is needed to find common and diverse biomolecular pathways. Circulating levels of 87 cytokines were compared amongst 19 healthy controls and consecutive patients with SSc-ILD (n\u2009=\u200939), SSc without ILD (n\u2009=\u200929), and IPF (n\u2009=\u200917) recruited from a Canadian centre using a log-linear model adjusted for age, sex, baseline forced vital capacity (FVC), and immunosuppressive or anti-fibrotic treatment at time of sampling. Also examined was annualized change in FVC. Four cytokines had Holm\u2019s corrected p-values less than 0.05. Eotaxin-1 levels were increased approximately two-fold in all patient categories compared to healthy controls. Interleukin-6 levels were eight-fold higher in all ILD categories compared to healthy controls. MIG\/CXCL9 levels increased two-fold more in all but one patient category compared to healthy controls. Levels of a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13, (ADAMTS13) were lower for all categories of patients compared to controls. No substantial association was found for any of the cytokines with FVC change. Observed cytokine differences suggest both common and diverse pathways leading to pulmonary fibrosis. Further studies evaluating longitudinal change of these molecules would be informative.<\/jats:p>","DOI":"10.1038\/s41598-023-31232-4","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T10:04:24Z","timestamp":1682330664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Circulating cytokine levels in systemic sclerosis related interstitial lung disease and idiopathic pulmonary fibrosis"],"prefix":"10.1038","volume":"13","author":[{"given":"Boyang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin J.","family":"Fritzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearce","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basak","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James V.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"issue":"4","key":"31232_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/acr.21583","volume":"64","author":"Steele R, Hudson M, Lo E, Baron M, Canadian Scleroderma Research G","year":"2012","unstructured":"Steele R, Hudson M, Lo E, Baron M, Canadian Scleroderma Research G. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res. 64(4), 519\u2013524 (2012).","journal-title":"Arthritis Care Res."},{"issue":"6","key":"31232_CR2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker, U. A. et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann. Rheum. Dis. 66(6), 754\u2013763 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"31232_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.rmed.2018.12.015","volume":"147","author":"P Heukels","year":"2019","unstructured":"Heukels, P., Moor, C. C., von der Th\u00fcsen, J. H., Wijsenbeek, M. S. & Kool, M. Inflammation and immunity in IPF pathogenesis and treatment. Respir. Med. 147, 79\u201391 (2019).","journal-title":"Respir. Med."},{"key":"31232_CR4","doi-asserted-by":"publisher","first-page":"3562923","DOI":"10.1155\/2016\/3562923","volume":"2016","author":"CJ Ryerson","year":"2016","unstructured":"Ryerson, C. J. et al. The Canadian registry for pulmonary fibrosis: design and rationale of a national pulmonary fibrosis registry. Can. Respir. J. 2016, 3562923 (2016).","journal-title":"Can. Respir. J."},{"issue":"11","key":"31232_CR5","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 72(11), 1747\u20131755 (2013).","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"31232_CR6","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu, G. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 198(5), e44\u2013e68 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"31232_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu, G. et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183(6), 788\u2013824 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"31232_CR8","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm, S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6(2), 65\u201370 (1979).","journal-title":"Scand. J. Stat."},{"key":"31232_CR9","unstructured":"R Core Team.  R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, 2022)."},{"key":"31232_CR10","unstructured":"PASS 2022. Power Analysis and Sample Size Software. (NCSS, LLC, 2022)."},{"issue":"3","key":"31232_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/rr52","volume":"2","author":"DM Conroy","year":"2001","unstructured":"Conroy, D. M. & Williams, T. J. Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir. Res. 2(3), 150 (2001).","journal-title":"Respir. Res."},{"issue":"6","key":"31232_CR12","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0002-9440(10)61235-7","volume":"167","author":"F Huaux","year":"2005","unstructured":"Huaux, F. et al. Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. Am. J. Pathol. 167(6), 1485\u20131496 (2005).","journal-title":"Am. J. Pathol."},{"issue":"6","key":"31232_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1183\/09031936.00028209","volume":"34","author":"P Beirne","year":"2009","unstructured":"Beirne, P. et al. Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur. Respir. J. 34(6), 1376\u20131382 (2009).","journal-title":"Eur. Respir. J."},{"issue":"10","key":"31232_CR14","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1093\/ndt\/gfs408","volume":"27","author":"D Mangieri","year":"2012","unstructured":"Mangieri, D. et al. Eotaxin\/CCL11 in idiopathic retroperitoneal fibrosis. Nephrol. Dial. Transplant. 27(10), 3875\u20133884 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"7362","key":"31232_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature10357","volume":"477","author":"SA Villeda","year":"2011","unstructured":"Villeda, S. A. et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477(7362), 90\u201394 (2011).","journal-title":"Nature"},{"issue":"1","key":"31232_CR16","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.1038\/s41598-017-05654-w","volume":"7","author":"E Kindstedt","year":"2017","unstructured":"Kindstedt, E. et al. CCL11, a novel mediator of inflammatory bone resorption. Sci. Rep. 7(1), 5334 (2017).","journal-title":"Sci. Rep."},{"issue":"1","key":"31232_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13075-020-02360-3","volume":"22","author":"E Raschi","year":"2020","unstructured":"Raschi, E. et al. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. Arthritis Res. Ther. 22(1), 265 (2020).","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"31232_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1165\/rcmb.2016-0121TR","volume":"55","author":"S Kolahian","year":"2016","unstructured":"Kolahian, S., Fernandez, I. E., Eickelberg, O. & Hartl, D. Immune mechanisms in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 55(3), 309\u2013322 (2016).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"10","key":"31232_CR19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna, D. et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 8(10), 963\u2013974 (2020).","journal-title":"Lancet Respir. Med."},{"key":"31232_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.cyto.2017.08.019","volume":"102","author":"SA Papiris","year":"2018","unstructured":"Papiris, S. A. et al. High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations. Cytokine 102, 168\u2013172 (2018).","journal-title":"Cytokine"},{"issue":"12","key":"31232_CR21","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3899\/jrheum.120506","volume":"39","author":"MC C\u00e9nit","year":"2012","unstructured":"C\u00e9nit, M. C. et al. Influence of the IL6 gene in susceptibility to systemic sclerosis. J. Rheumatol. 39(12), 2294\u20132302 (2012).","journal-title":"J. Rheumatol."},{"issue":"4","key":"31232_CR22","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1038\/cti.2013.2","volume":"2","author":"S O'Reilly","year":"2013","unstructured":"O\u2019Reilly, S., Cant, R., Ciechomska, M. & van Laar, J. M. Interleukin-6: A new therapeutic target in systemic sclerosis?. Clin. Transl. Immunol. 2(4), e4 (2013).","journal-title":"Clin. Transl. Immunol."},{"issue":"8","key":"31232_CR23","first-page":"914","volume":"88","author":"PM Mannucci","year":"2003","unstructured":"Mannucci, P. M., Vanoli, M., Forza, I., Canciani, M. T. & Scorza, R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 88(8), 914\u2013918 (2003).","journal-title":"Haematologica"},{"issue":"2","key":"31232_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5114\/ada.2018.75240","volume":"35","author":"Z Gerlicz-Kowalczuk","year":"2018","unstructured":"Gerlicz-Kowalczuk, Z. et al. ADAMTS13 deficiency and immunological abnormalities in patients with systemic sclerosis. Postepy Dermatol. Alergol. 35(2), 182\u2013184 (2018).","journal-title":"Postepy Dermatol. Alergol."},{"issue":"1","key":"31232_CR25","doi-asserted-by":"publisher","first-page":"R18","DOI":"10.1186\/ar3242","volume":"13","author":"BJ Rabquer","year":"2011","unstructured":"Rabquer, B. J. et al. Dysregulated expression of MIG\/CXCL9, IP-10\/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthrit. Res. Ther. 13(1), R18 (2011).","journal-title":"Arthrit. Res. Ther."},{"issue":"4","key":"31232_CR26","first-page":"e178","volume":"169","author":"F Ragusa","year":"2018","unstructured":"Ragusa, F. MIG chemokine in systemic sclerosis. MIG in Systemic sclerosis. Clin Ter. 169(4), e178\u2013e183 (2018).","journal-title":"Clin Ter."},{"issue":"6","key":"31232_CR27","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.4049\/jimmunol.1402008","volume":"195","author":"SL O'Beirne","year":"2015","unstructured":"O\u2019Beirne, S. L. et al. CXCL9 regulates TGF-beta1-induced epithelial to mesenchymal transition in human alveolar epithelial cells. J. Immunol. 195(6), 2788\u20132796 (2015).","journal-title":"J. Immunol."},{"issue":"2","key":"31232_CR28","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.chest.2020.03.037","volume":"158","author":"Y Inoue","year":"2020","unstructured":"Inoue, Y. et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest 158(2), 646\u2013659 (2020).","journal-title":"Chest"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31232-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31232-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31232-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T22:03:10Z","timestamp":1682373790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31232-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["31232"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-31232-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"21 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KK has received honoraria from Merck Canada Inc, Hoffman-La Roche Ltd., Pfizer Canada. MF is medical director of Mitogen Diagnostics Inc. and has received honoraria from diagnostic companies Werfen and Aesku. CR has received grants from Boehringer Ingelheim, Hoffmann-La Roche and consulting fees from Boehringer Ingelheim, Hoffmann-La Roche, Astra Zeneca, Veracyte, Ensho, Pliant Therapeutics. PW has received honoraria from Vertex, Valeo, and Boehringer Ingelheim. JVD has received\u00a0consulting fees from Boehringer Ingelheim.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6647"}}